The immunotargeting approach to adjuvant-independent subunit vaccine design

Seminars in Immunology

Volumn 9, Issue 5, 1997, Pages 293-301

  Barber, Brian H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adjuvants; Antigen presenting cells; Immunotargeting; Recombinant antibodies; Vaccines

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; SECRETORY IMMUNOGLOBULIN; VACCINE;

ANIMAL MODEL; ANTIGEN PRESENTING CELL; DRUG DESIGN; DRUG TARGETING; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; REVIEW;

EID: 0031251876     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.1997.0085     Document Type: Article

References (50)

1. 1. Pollock RR, Teillaud J-L, Scharff MD (1984) Monoclonal antibodies: a powerful tool for selecting and analysing mutations in antibodies and antigens. Annu Rev Microbiol 38:389-417
2. 2. Singer A, Modes RJ (1983) Mechanism of T-cell-B-cell interaction. Annu Revlmmunol 1:211-241
3. 3. Ellis RW (1988) New technologies for making vaccines, in Vaccines (Plotkin SA, Mortimer EA, eds) pp 568-575. W.B. Saunders Co., Philadelphia
4. 4. Steward MW, Howard CR (1987) Synthetic peptides: a next generation of vaccines?. Immunol Today 8:51-58
5. 5. Milich DR (1989) Synthetic T and B cell recognition sites: implications for vaccine development. Adv Immunol 45:195-282
6. 6. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efrain S, Gupta GK (1993) Adjuvants: a balance between toxicity and adjuvanticity. Vaccine 11:293-300
7. 7. Audibert FM, Lise LD (1993) Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 14:281-284
8. 8. O'Hagan DT, Ott GS, Van Nest G (1997) Recent advances in vaccine adjuvants: the development of Mf59 emulsion and polymeric microparticles. Molec Immunol Today Feb 1997: 69-75
9. 9. Kawamura H, Berzofsky JA (1986) Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J Immunol 136:58-65
10. 10. Carayanniotis G, Barber BH (1987) Adjuvant-free IgG responses induced with antigen coupled to antibodies against class I MHC. Nature 327:59-61
11. 11. Pierce SK, Casten LA (1988) Soluble globular protein antigens covalently coupled to antibodies specific for B-cell surface structures are effective antigens both in vitro and in vivo, in Antigen Presenting Cells: Diversity, Differentiation and Regulation (Schook LB, Tew JG, eds) pp 259-268. Alan R. Liss, Inc., New York
12. 12. Casten LA, Kaumaya P, Pierce SK (1988) Enhanced T-cell responses to antigenic peptides targeted to B-cell surface Ig, Ia or class I molecules. J Immunol 168:171-180
13. 13. Snider DP, Segal DM (1987) Targeted antigen presentation using crosslinked antibody heteroconjugates. J Immunol 139:1609-1616
14. 14. Snider DP, Kaubisch A, Segal DM (1990) Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med 171:1957-1963
15. 15. Snider DP (1992) Immunization with antigen bound to bispecific antibody induces antibody that is restricted in epitope specificity and contains anti-idiotype. J Immunol 148:1163-1170
16. 16. Mjaaland S, Fossum S (1990) Modulation of immune responses with monoclonal antibodies I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies. Eur J Immunol 20:1457-1461
17. 17. Carayanniotis G, Skea DL, Luscher M, Barber BH (1991) Adjuvant-independent immunization by immunotargeting antigens to MHC and non-MHC determinants in vivo. Molec Immunol 28:261-267
18. 18. Nussenzweig NC, Steinman RM, Witmer MD, Gutchirov B (1982) A monoclonal antibody specific for mouse dendritic cells. Proc Natl Acad Sci USA 79:161-165
19. 19. Skea DL, Barber BH (1993) Studies of the adjuvant-independent antibody response to immunotargeting. J Immunol 151:3557-3568
20. 20. Sornasse T, Flamand V, De Becker G, Thielmens K, Urbain J, Leo O, Moser M (1993) Loading of dendritic cells with antigen in vitro or in vivo by immunotargeting can replace the need for adjuvant, in Dendritic Cells in Fundamental and Clinical Immunology (Kamperdijk et al, ed) pp 299-303. Plenum Press, New York
21. 21. Mjaaland S, Fossum S (1991) Antigen targeting with monoclonal antibodies as vectors II. Further evidence that conjugation of antigen to specific monoclonal antibodies enhances uptake by antigen presenting cells. Int Immunol 3:1315-1321
22. 22. Kremmer E, Mysliwietz J, Lederer R, Thierfelder S (1993) Murine anti-mouse T-cell monoclonal antibodies elicit antiantibodies in mice: intra-species immunization model for estimating potential patient sensitization against humanized anti-T-cell antibodies. Eur J Immunol 23:1017-1022
23. 23. Lees A, Morris SC, Thyphronitis G, Holmes JM, Inman JK, Finkelman FD (1990) Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J Immunol 145:3594-3600
24. 24. Berg SF, Mjaaland S, Fossum S (1994) Comparing macrophages and dendritic leukocytes as antigen presenting cells for humoral responses in vivo by antigen targeting. Eur J Immunol 24:1262-1268
25. 25. Squire CM, Studer EJ, Lees A, Finkelman FD, Conrad DH (1994) Antigen presentation enhanced by targeting antigen to the FcεRII by antigen-anti-FcεRII conjugates. J Immunol 152:4388-4396
26. 26. Possum S, Berg SF, Mjaaland S (1992) Targeting antigens to antigen presenting cells. Semin Immunol 4:275-283
27. 27. Liu C, Guyre PM (1995) Antigen targeting, in Bispecific Antibodies (Fanger MW, ed) pp 133-145. R.G. Landes Co., Austin
28. 28. Carayanniotis G, Barber BH (1990) Characteristics of the adjuvant-free serological response to protein antigens coupled to antibodies specific for class II MHC determinants. Vaccine 8:137-144
29. 29. Tiong GKL, Gill HS, Lofthouse S, Puri NK (1992) Comparison of conventional adjuvants and adjuvant-free monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin. Vaccine 11:425-430
30. 30. Skea DL, Douglas AR, Skehel JJ, Barber BH (1993) The immunotargeting approach to adjuvant-independent immunization with influenza hemagglutinin. Vaccine 11:994-1002
31. 31. Dubiski S, Cinader B, Chou CT, Charpentier L, Letarte M (1988) Cross reaction of a monoclonal antibody to human MHC class II molecules with rabbit B cells. Molec Immunol 25:713-718
32. 32. Baier G, Baier-Bitterlich G, Looney DJ, Altman A (1995) Immunogenic targeting of recombinant peptide vaccines to human antigen presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D Fab fragments in vitro. J Virol 69:2357-2365
33. 33. Staats HF, Jackson RJ, Marinaro M, Takahashi I, Kiyono H, McGhee JR (1994) Mucosal immunity to infection with implications for vaccine development. Curr Opin Immuol 6:572-578
34. 34. Estrada A, McDermott MR, Underdown BJ, Snider DP (1995) Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Vaccine 13:901-907
35. 35. Elson CO, Ealding W (1984) Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132:2736-2742
36. 36. Snider DP, Underdown BJ, McDermott MR (1997) Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice. Immunology 90:323-329
37. 37. Van Regenmortel MHV (1989) Structural and functional approaches to the study of protein antigenicity. Immunol Today 10:266-272
38. 38. Carayanniotis G, Vizi E, Parker JMR, Hodges RS, Barber BH (1988) Delivery of synthetic peptides by anti-class II MHC monoclonal antibodies induces specific adjuvant-free IgG responses in vivo. Molec Immunol 25:907-911
39. 39. Brumeanu TD, Casares S, Harris PE, Dehazya P, Wolf I, von Boehmer H, Bona CA (1996) Immunopotency of a viral peptide assembled on the carbohydrate moieties of self immunoglobulins. Nature Biotech 14:722-725
40. 40. Kumar A, Arora R, Kaur P, Chouhan VS, Sharm P (1992) Universal T helper cell determinants enhance immunogenicity of a plasmodium falciparum merozoite surface antigen peptide. J Immunol 148:1499-1505
41. 41. Zanetti M (1992) Antigenized antibodies. Nature 355:476-477
42. 42. Billetta R, Hollingdale MR, Zanetti M (1991) Immunogenicity of an engineered internal image antibody. Proc Natl Acad Sci USA 88:4713-4717
43. 43. Lanza P, Billetta R, Antonenko S, Zanetti M (1993) Active immunity against the CD4 receptor by using an antibody antigenized with the residues 41-55 of the first extracellular domain. Proc Natl Acad Sci USA 90:11683-11687
44. 44. Rossi F, Billetta R, Ruggeri Z, Zanetti M (1995) Engineered idiotypes: immunological analysis of antigenized antibodies expressing a conformationally constrained Arg-Gly-Asp motif. Molec Immunol 32:341-346
45. 45. Cook J, Barber BH (1995) Recombinant antibodies containing engineered B-cell epitopes capable of eliciting conformation-specific antibody responses. Vaccine 13:1770-1778
46. 46. Muller S, Plaue S, Samama JP, Valette M, Briand JP, Van Regenmortel MHV (1990) Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus hemagglutinin. Vaccine 8:308-314
47. 47. Zaghouani H, Anderson SA, Sperber KE, Daian C, Kennedy RC, Mayer L, Bona CA (1995) Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein. Proc Natl Acad Sci USA 92:631-635
48. 48. Cook J, Barber BH (1997) Recombinant antibodies with conformationally constrained HIV type 1 epitope inserts elicit glycoprotein 160-specific antibody responses in vivo. AIDS Res Hum Retroviruses 13:449-460
49. 49. Brumeanu TD, Swiggard WJ, Steinman RM, Bona CA, Zaghouani H (1993) Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus. J Exp Med 178:1795-1799
50. 50. Brumeanu TD, Zaghouani H, Elahi E, Daian C, Bona CA (1995) Derivatization with monomethoxypolyethylene glycol of Igs expressing viral epitopes obviates adjuvant requirements. J Immunol 154:3088-3095